{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:18:50Z","timestamp":1788520730743,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stromal tumor-infiltrating lymphocytes (TILs) are established biomarkers in triple-negative breast cancer (TNBC), but conventional density-based assessment does not capture their spatial relationship to tumor nests. We evaluated whether an H&amp;amp;E-derived spatial architecture index (SAI) provides predictive information beyond stromal TIL density for pathologic complete response (pCR) after neoadjuvant therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort included 236 patients with TNBC who had evaluable pretreatment core biopsy slides and definitive surgical response assessment. The primary SAI was the equally weighted mean of standardized close interaction ratio and lymphocyte cluster index, together with reverse-coded standardized lymphocyte\u2013tumor distance and edge enrichment. The primary multivariable analysis included 231 patients with complete clinicopathologic data. Robustness was evaluated using bootstrap optimism correction, alternative SAI constructions, treatment-regimen and propensity-score analyses, repeated nested cross-validation, and a 60-case reproducibility assessment. During internal validation, preprocessing and SAI construction were repeated within each training fold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 236 patients, 122 (51.7%) achieved pCR. In the main multivariable model, the SAI remained associated with pCR (OR 2.79 per 1 SD, 95% CI 1.79\u20134.35;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001), whereas stromal TIL density was not independently significant (OR 0.88 per 10% increase, 95% CI 0.74\u20131.04;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.123). Bootstrap optimism-corrected AUROCs were 0.698 for the clinical model, 0.705 after the addition of stromal TIL density, 0.764 after the addition of the SAI, and 0.765 after the addition of both. Across six internally validated algorithms using the full feature set, mean AUROCs ranged from 0.730 to 0.752, with only modest between-algorithm differences. The SAI showed excellent interobserver reproducibility (ICC 0.93, 95% CI 0.89\u20130.95). Its association with pCR persisted in the chemotherapy-only subgroup (OR 2.48, 95% CI 1.52\u20134.05;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001), whereas the interaction with pembrolizumab-containing treatment was not significant (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.222).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this exploratory single-center retrospective cohort, the H&amp;amp;E-derived SAI provided internally validated predictive information beyond stromal TIL density for pCR. External multicenter validation, assessment of intersite technical reproducibility, and prospective calibration are required before clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1879640","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:41:29Z","timestamp":1788417689000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatial architecture of tumor-infiltrating lymphocytes adds predictive value beyond stromal TIL density for neoadjuvant response in triple-negative breast cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Ke","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Chengdu Xinhua Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Huang","sequence":"additional","affiliation":[{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[{"name":"Beijing Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Neijiang Hospital of Traditional Chinese Medicine","place":["Neijiang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Hao","sequence":"additional","affiliation":[{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Chengdu Xinhua Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet (London England)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s1470-2045(17)30904-x","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13000-018-0743-7","article-title":"Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers","volume":"13","author":"Ruan","year":"2018","journal-title":"Diagn Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133275","article-title":"Predictive roles of baseline stromal tumor-infiltrating lymphocytes and Ki-67 in pathologic complete response in an early-stage triple-negative breast cancer prospective trial","volume":"15","author":"Abuhadra","year":"2023","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","article-title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/pap.0000000000000161","article-title":"Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anatomic Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/his.14328","article-title":"Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry\/immunofluorescence","volume":"79","author":"Tien","year":"2021","journal-title":"Histopathology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/path.6061","article-title":"Artificial intelligence-based digital scores of stromal tumour-infiltrating lymphocytes and tumour-associated stroma predict disease-specific survival in triple-negative breast cancer","volume":"260","author":"Albusayli","year":"2023","journal-title":"J Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092148","article-title":"Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression","volume":"14","author":"Fassler","year":"2022","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154476","article-title":"Whole slide image features predict pathologic complete response and poor clinical outcomes in triple-negative breast cancer","volume":"246","author":"Hacking","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.03.012","article-title":"Utilizing automated breast cancer detection to identify spatial distributions of tumor-infiltrating lymphocytes in invasive breast cancer","volume":"190","author":"Le","year":"2020","journal-title":"Am J Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1186\/s12885-024-12962-8","article-title":"Automated scoring methods for quantitative interpretation of tumour infiltrating lymphocytes (TILs) in breast cancer: a systematic review","volume":"24","author":"Baharun","year":"2024","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102467","article-title":"Development of training materials for pathologists to provide machine learning validation data of tumor-infiltrating lymphocytes in breast cancer","volume":"14","author":"Garcia","year":"2022","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102928","article-title":"The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably","volume":"78","author":"Vidal","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143635","article-title":"Automated detection and scoring of tumor-infiltrating lymphocytes in breast cancer histopathology slides","volume":"15","author":"Yosofvand","year":"2023","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ (Clinical Res Ed)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.ad","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Internal Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.109","article-title":"Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group","volume":"29","author":"Denkert","year":"2016","journal-title":"Modern Pathol Off J United States Can Acad Pathology Inc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decision Making Int J Soc For Med Decision Making"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13058-023-01752-y","article-title":"Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer","volume":"26","author":"Fisher","year":"2024","journal-title":"Breast Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41523-025-00728-9","article-title":"Spatial proximity of CD8(+) T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer","volume":"11","author":"Liang","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10469-9","article-title":"Ecotypes of triple-negative breast cancer in response to chemotherapy","volume":"654","author":"Yan","year":"2026","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4143\/crt.2016.215","article-title":"Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer","volume":"49","author":"Song","year":"2017","journal-title":"Cancer Res Treat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.086","article-title":"Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images","volume":"23","author":"Saltz","year":"2018","journal-title":"Cell Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.774088","article-title":"Intratumoral heterogeneity and immune response indicators to predict overall survival in a retrospective study of HER2-borderline (IHC 2+) breast cancer patients","volume":"11","author":"Radziuviene","year":"2021","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41591-023-02643-7","article-title":"A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer","volume":"30","author":"Amgad","year":"2024","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1038\/s41467-026-72956-x","article-title":"Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge","volume":"17","author":"Rijthoven","year":"2026","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.6155","article-title":"Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"260","author":"Thagaard","year":"2023","journal-title":"J Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-020-0154-2","article-title":"Report on computational assessment of tumor infiltrating lymphocytes from the International Immuno-Oncology Biomarker Working Group","volume":"6","author":"Amgad","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1879640\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:00:17Z","timestamp":1788519617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1879640\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1879640"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1879640","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1879640"}}